Eli Lilly’s Insulin Price Cuts Pressure Other Producers to Follow Suit

In the midst of swirling controversy about high insulin prices, Eli Lilly has announced that it’s reducing the cost of its most commonly prescribed — and older — insulins by 70 percent and expanding its program that caps patient out-of-pocket costs at $35 per month.
Source: Drug Industry Daily